DOP2014000294A - Purificación de iduronato 2 sulfatasa - Google Patents

Purificación de iduronato 2 sulfatasa

Info

Publication number
DOP2014000294A
DOP2014000294A DO2014000294A DO2014000294A DOP2014000294A DO P2014000294 A DOP2014000294 A DO P2014000294A DO 2014000294 A DO2014000294 A DO 2014000294A DO 2014000294 A DO2014000294 A DO 2014000294A DO P2014000294 A DOP2014000294 A DO P2014000294A
Authority
DO
Dominican Republic
Prior art keywords
protein
iduronate
sulfatase
purification
present
Prior art date
Application number
DO2014000294A
Other languages
English (en)
Spanish (es)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of DOP2014000294A publication Critical patent/DOP2014000294A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DO2014000294A 2012-06-29 2014-12-19 Purificación de iduronato 2 sulfatasa DOP2014000294A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
DOP2014000294A true DOP2014000294A (es) 2015-03-15

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000294A DOP2014000294A (es) 2012-06-29 2014-12-19 Purificación de iduronato 2 sulfatasa

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP3441398A1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN107596358A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA2877517C (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA034549B1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL287057B2 (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY180287A (enExample)
NZ (3) NZ703093A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871B1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI553120B (enExample)
UA (2) UA129561C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184105A1 (en) 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製
MX2021008983A (es) * 2019-01-30 2021-09-08 Amgen Inc Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2021364779B2 (en) * 2020-10-23 2026-08-13 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
EP1212343A4 (en) 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
WO2001070804A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
US20100190210A1 (en) 2006-03-20 2010-07-29 Medarex, Inc. Protein Purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
PL3219795T3 (pl) 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
KR20130043165A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
CN103269709A (zh) * 2010-06-25 2013-08-28 夏尔人类遗传性治疗公司 Sanfilippo综合症类型B的治疗
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
PL2867245T3 (pl) 2019-02-28
US9492511B2 (en) 2016-11-15
AU2018200230B2 (en) 2020-01-02
WO2014005014A3 (en) 2014-02-27
KR20140004603A (ko) 2014-01-13
IL236315A0 (en) 2015-02-26
US20170073652A1 (en) 2017-03-16
BR112014032567A2 (pt) 2017-08-01
US20150313972A1 (en) 2015-11-05
UA121959C2 (uk) 2020-08-25
KR101380740B1 (ko) 2014-04-11
IL261264B (en) 2021-10-31
IL261264A (en) 2018-10-31
KR20220002227A (ko) 2022-01-06
CY1121519T1 (el) 2020-05-29
MX393364B (es) 2025-03-19
HK1209431A1 (en) 2016-04-01
WO2014005014A2 (en) 2014-01-03
IL248727A0 (en) 2017-01-31
PH12020500027A1 (en) 2021-03-15
JP6171007B2 (ja) 2017-07-26
US12359178B2 (en) 2025-07-15
US20240401010A1 (en) 2024-12-05
CA2877517C (en) 2018-07-31
EA034549B1 (ru) 2020-02-19
MX366906B (es) 2019-07-30
AU2013282395C1 (en) 2016-03-24
SG10201703489VA (en) 2017-05-30
PT2867245T (pt) 2018-11-26
AU2013282395A1 (en) 2015-01-29
PH12014502871A1 (en) 2015-02-23
SG11201408761VA (en) 2015-01-29
NZ703093A (en) 2017-08-25
MX336715B (es) 2016-01-28
MY157087A (en) 2016-04-19
PH12014502871B1 (en) 2015-02-23
CN107596358A (zh) 2018-01-19
JP6505629B2 (ja) 2019-04-24
US20210317426A1 (en) 2021-10-14
BR112014032567B1 (pt) 2022-09-13
EP3441398A1 (en) 2019-02-13
AU2016200469B2 (en) 2017-10-12
IL287057A (en) 2021-12-01
JP2016119911A (ja) 2016-07-07
EA202090044A1 (ru) 2020-07-31
NZ733366A (en) 2019-12-20
CA2877517A1 (en) 2014-01-03
NZ743910A (en) 2019-12-20
GT201400303A (es) 2017-08-31
CN104583225A (zh) 2015-04-29
CN107596357A (zh) 2018-01-19
RS58005B1 (sr) 2019-02-28
CA3008945A1 (en) 2014-01-03
IL287057B2 (en) 2026-05-01
CO7240396A2 (es) 2015-04-17
US20190359958A1 (en) 2019-11-28
TR201815811T4 (tr) 2018-11-21
IL287057B1 (en) 2026-01-01
US9051556B2 (en) 2015-06-09
JP7594365B2 (ja) 2024-12-04
PE20150720A1 (es) 2015-05-16
UA129561C2 (uk) 2025-06-04
DK2867245T3 (en) 2018-11-26
AR091647A1 (es) 2015-02-18
TWI553120B (zh) 2016-10-11
EA201492177A1 (ru) 2015-06-30
HRP20181897T1 (hr) 2019-01-11
KR20190064542A (ko) 2019-06-10
AU2013282395B2 (en) 2015-12-03
TW201410868A (zh) 2014-03-16
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
HK1249027A1 (zh) 2018-10-26
MX2019008914A (es) 2019-09-26
PH12015502408B1 (en) 2020-02-14
IL236315A (en) 2016-11-30
SI2867245T1 (sl) 2018-12-31
JP2015523072A (ja) 2015-08-13
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
LT2867245T (lt) 2018-11-12
EP2867245A2 (en) 2015-05-06
US20140004096A1 (en) 2014-01-02
MY180287A (en) 2020-11-27
US11530393B2 (en) 2022-12-20
KR20200143339A (ko) 2020-12-23
JP2018121645A (ja) 2018-08-09
SMT201800612T1 (it) 2019-01-11
ZA201803289B (en) 2021-04-28
MX2015000190A (es) 2015-04-08
TWI587869B (zh) 2017-06-21
EP2867245A4 (en) 2016-03-09
ES2689468T3 (es) 2018-11-14
ZA201409397B (en) 2019-10-30
HK1249026A1 (zh) 2018-10-26
AU2016200469A1 (en) 2016-02-18
JP2020105209A (ja) 2020-07-09
AU2018200230A1 (en) 2018-02-01
EP2867245B1 (en) 2018-09-12
MY192068A (en) 2022-07-25
PH12015502408A1 (en) 2018-03-26
TW201703794A (zh) 2017-02-01
HUE040769T2 (hu) 2019-03-28
CL2014003567A1 (es) 2015-04-24
US20240043817A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
CO7240396A2 (es) Purificación de iduronato-2-sulfatasa
MX344970B (es) Medio de cultivo celular para la expresion de la proteina adamts.
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
BRPI0917993B8 (pt) composições de célula-tronco mesenquimal purificada
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
MX2010000944A (es) Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones.
BR112015009774A2 (pt) polipeptídeos citocromo p450 e citocromo p450 redutase, codificando moléculas de ácido nucléicos e usos das mesmas
BR112014001978A2 (pt) proteínas variantes axmi205 e métodos para a utilização das mesmas
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
BR112014002173A2 (pt) proteínas purificadas
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
MX363187B (es) Métodos y composiciones para impedir la incorrecta incorporación de norleucina en proteínas.
ATE533501T1 (de) Verwendung des ped-faktors zur induktion von zellregenerierung
BR112012033396A2 (pt) Polipetídeo tendo atividade swollenin e seus usos.
BR112015020253A2 (pt) formulações e métodos para produção aumentada de proteína recombinante
DE502006002664D1 (de) Verfahren zur herstellung von lipasen
NZ742412A (en) Methods and compositions for preventing norleucine misincorporation into proteins
FI20115976A0 (fi) Proteolyyttisen entsyymin käyttö